News

US FDA to phase out animal testing in drug development
The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...
FDA says it will phase out animal testing requirement for monoclonal antibodies and drugs
The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...
FDA to phase out some animal testing requirements, possibly replace them with AI models
The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological ...
Axios on MSN10h
FDA plans to phase out animal testing requirements
The Food and Drug Administration on Thursday said it would begin phasing out animal testing requirements for antibody ...
FDA to phase out animal testing requirement, adopt AI methods
The FDA is phasing out animal testing for monoclonal antibody therapies, embracing AI and human-based models. Read more here.
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food ...
To promote drug safety, FDA to replace animal testing with AI-based experiments, other methods
The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...
UC San Diego Today23h
Meet us at Phase 0: Inside the HUMANOID™ Center at UC San Diego
Ghosh is at the helm of the HUMANOID™ Center for Excellence at the University of California San Diego, which is pioneering ...
pharmaphorum2d
Sumitomo's novel schizophrenia drug flunks phase 3 test
After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.
FDA to phase out animal testing requirement for monoclonal antibodies
The U.S. Food and Drug Administration is replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...